BPDCN
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies (NCT05476770) | Therapeutic Advances in Childhood Leukemia Consortium | 2022-11-11 |
| CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) (NCT04318678) | St. Jude Children's Research Hospital | 2020-07-29 |
Track BPDCN automatically
Every clearance here is in the API, with alerts when new ones post.